SynthesisBMC pulmonary medicine2025
Potential drug targets for chronic obstructive pulmonary disease in the plasma proteome identified through Mendelian randomization.
Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Current options such as glucocorticoids and bronchodilators improve symptoms but carry risks, including infection and immunosuppression. To guide safer, mechanism-based therapies and biomarker discovery, we genetically prioritize circulating proteins.
methodsWe used the integrated dataset from Sun et al., which combined seven large-scale plasma proteome GWAS covering 4,853 proteins measured on SOMAscan, Olink, and xMAP platforms, to evaluate the causal effects of circulating proteins on COPD through two-sample Mendelian randomization (MR). Only genome-wide significant cis-pQTLs (P < 5 × 10⁻⁸) with F > 10 were retained after LD clumping. Discovery analysis was performed with FinnGen R10 COPD GWAS (20,066 cases, 338,303 controls), and replication analyses with deCODE (35,559 individuals, 4,907 proteins) and the Million Veteran Program (103,054 cases, 315,450 controls). Results were meta-analyzed and validated using Bayesian colocalization, Steiger tests, proteome-wide association study (PWAS, ARIC cohort), and protein-protein interaction (PPI) analysis.
resultsEleven proteins showed significant associations with COPD risk in the discovery stage (FDR < 0.05), including risk-enhancing MST1, TIE1, and PILRA, and protective ERAP2, PILRB, SERPING1, SNX1, IL17RD, STARD5, IL27RA, and TNFRSF6B. Replication confirmed consistent effects for five proteins, with IL17RD, IL27RA, and TIE1 remaining significant. Meta-analysis provided robust evidence for IL27RA (OR = 0.97, 95% CI: 0.95-0.98, P = 1.0×10-6) and TIE1 (OR = 1.14, 95% CI: 1.07-1.21, P = 4.8×10⁻⁵), while IL17RD was nominally significant. ERAP2 and SNX1 did not replicate. PWAS supported ERAP2, TIE1, IL27RA, and SMPD1, and PPI revealed functional interactions of IL27RA, MMP12, and TIE1 with known COPD drug targets.
conclusionBy integrating MR, replication, meta-analysis, PWAS, and PPI, our findings genetically nominate IL27RA, IL17RD, and TIE1 as putative candidates for therapeutic investigation and/or biomarker development in COPD. Further mechanistic and pharmacological studies are required before any treatment claims can be made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.